Search for Anti-Androgen Compounds to Overcome Resistance of Current Drugs

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$241,752.00
Award Year:
2006
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA119673-01A1
Award Id:
80076
Agency Tracking Number:
CA119673
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
SHIFA BIOMEDICAL, GREAT VALLEY CORPORATE CENTER, MALVERN, PA, 19355
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
SHERIN ABDELMEGUID
(617) 828-1106
SHERIN2@AOL.COM
Business Contact:
SHERIN ABDEL-MEGUID
(617) 828-1108
sherin2@aol.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The long-term goal of this work is to develop new prostate cancer drugs that overcome the resistance seen with current marketed anti-androgen drugs (androgens are male sex hormones). The specific aim of the proposed work is to identify novel lead compounds that work by a different mechanism than that of current drugs. As with current drugs our molecular target will be the androgen receptor. But unlike current drugs that are competive antagonists of androgens' binding to the androgen receptor, our compounds will interfere with the interaction between the androgen receptor and its co-regulator proteins. To that end, we will integrate virtual (computer) screening methods, cell-based assays and crystal structure determinations to identify lead compounds that can potentially be optimized to produce a drug for the treatment of prostate cancer. Virtual screening, which requires the availability of atomic resolution 3D structures of the target protein, provides a cost effective way to screen million of compounds to identify just a few to be purchased and tested in a biological or biochemical assay. Our access to such 3D structures of the androgen receptor ligand binding domain makes this work possible. The specific aims of this work are to: 1. Utilize virtual screening methods to screen millions of compound for their proper docking into the androgen receptor co-regulator site, as defined by our atomic resolution 3D structures of the androgen receptor ligand binding domain. 2. Select and purchase a few hundred compounds that are "drug like" and have high potential to be intestinally absorbed. 3. Test these compounds in a cell-based assay for their potential to disrupt transcriptional activation, and select the best compounds. 4. Confirm that the selected compounds bind at the co-regulator site using crystal structure determination of the androgen receptor's ligand binding domain in complex with each selected compound. Accomplishing the specific aims outlined in this proposal will provide the foundation for lead optimization and the potential development of novel prostate cancer drugs. Project Narrative: Prostate cancer, which accounts for 10% of male cancer-related deaths in the US, is the second leading cause of cancer death in American men, exceeded only by lung cancer. Although prostate cancer can be successfully treated with current marketed drugs, most of these drugs become ineffective after only a few years of treatment. Our goal is to develop new prostate cancer drugs that overcome the resistance seen with current marketed drugs.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government